Banco De Sabadell, S.A Bei Gene, Ltd. Transaction History

Banco De Sabadell, S.A

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 13, 2021	SELL	$292.75 - $367.01 $901,962 - $1.13 Million	-3,081 Closed	0 $0
Q1 2021 May 14, 2021	BUY	$260.64 - $382.12 $86,011 - $126,099	330 Added 12.0%	3,081 $1.03 Million
Q2 2020 Aug 07, 2020	BUY	$123.9 - $195.41 $340,848 - $537,572	2,751 New	2,751 $519,000

252

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $18.7B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Banco De Sabadell, S.A, based on Form 13F filings with the SEC.

Stay updated on Banco De Sabadell, S.A with notifications on news.